Condition
Invasive Ductal Carcinoma
Total Trials
5
Recruiting
0
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 60/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (3)
Early P 1 (1)
P 1 (1)
Trial Status
Terminated1
Completed1
Withdrawn1
Unknown1
Active Not Recruiting1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT01644669Not ApplicableActive Not RecruitingPrimary
Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System®
NCT04349111Not ApplicableWithdrawnPrimary
An Efficacy Study of the Xoft® Axxent® eBx® IORT System® "Lite"
NCT01796041Early Phase 1CompletedPrimary
Intraoperative Imaging of Breast Cancer With Indocyanine Green
NCT02365714Phase 1Terminated
CyberKnife Stereotactic Accelerated Partial Breast Irradiation (SAPBI)
NCT01038258Not ApplicableUnknownPrimary
Monitoring Response After The First Chemotherapy Cycle After Neoadjuvant Breast Cancer Therapy
Showing all 5 trials